Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Organon & Co.OGN · Entity 4115 | Chief Commercial Officer | September 03, 2024 | September 05, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Organon & Co.
Report date September 03, 2024 · Filed September 05, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 53,113 |
Ending reported balance
After 2024-09-03 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-09-03 · Grant · Acquired 3,594 · Balance 54,258 F1: Represents shares of Organon & Co. common stock for performance share units granted to the reporting person on August 17, 2021 under the Organon & Co. 2021 Incentive Stock Plan. The performance-vesting restrictions with respect to these shares were released upon certification of performance goal attainment by the Talent Committee of Organon's Board of Directors. Row 2 · 2024-09-03 · Tax withholding · Disposed 1,145 · Balance 53,113 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of Organon & Co. common stock for performance share units granted to the reporting person on August 17, 2021 under the Organon & Co. 2021 Incentive Stock Plan. The performance-vesting restrictions with respect to these shares were released upon certification of performance goal attainment by the Talent Committee of Organon's Board of Directors.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 02, 2021 Filed Jun 4, 2021 21:26 UTC | Organon & Co. OGN · Entity 4115 | GrantStock Option (Right to Buy) · Derivative | 26,123 | $0.00 Strike: $25.98 | $0.00 |
DisclosureSEC source: 0000899243-21-022198 · doc4.xml · derivative · entry 8 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,123 Underlying: Common Stock · 26,123 shares Expires 2026-05-09 F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 21:26 UTC | Organon & Co. OGN · Entity 4115 | GrantRestricted Stock Units · Derivative | 19,828 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-022198 · doc4.xml · derivative · entry 7 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,828 Underlying: Common Stock · 19,828 shares Expires 2023-12-31 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock. F6 · kind: In connection with the Separation, each outstanding Merck performance stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck performance stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. F8 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in a single installment on December 31, 2023. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 21:26 UTC | Organon & Co. OGN · Entity 4115 | GrantRestricted Stock Units · Derivative | 9,116 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-022198 · doc4.xml · derivative · entry 6 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,116 Underlying: Common Stock · 9,116 shares Expires 2022-12-31 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock. F6 · kind: In connection with the Separation, each outstanding Merck performance stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck performance stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. F7 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in a single installment on December 31, 2022. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 21:26 UTC | Organon & Co. OGN · Entity 4115 | GrantRestricted Stock Units · Derivative | 8,719 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-022198 · doc4.xml · derivative · entry 5 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,719 Underlying: Common Stock · 8,719 shares Expires 2021-12-31 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock. F6 · kind: In connection with the Separation, each outstanding Merck performance stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck performance stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 21:26 UTC | Organon & Co. OGN · Entity 4115 | GrantRestricted Stock Units · Derivative | 14,957 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-022198 · doc4.xml · derivative · entry 4 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,957 Underlying: Common Stock · 14,957 shares Expires 2024-05-04 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock. F3 · kind: In connection with the Separation, each outstanding Merck restricted stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck restricted stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. F5 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in three equal installments on May 4, 2022, May 4, 2023 and May 4, 2024. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 21:26 UTC | Organon & Co. OGN · Entity 4115 | GrantRestricted Stock Units · Derivative | 4,336 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-022198 · doc4.xml · derivative · entry 3 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,336 Underlying: Common Stock · 4,336 shares Expires 2023-05-01 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock. F3 · kind: In connection with the Separation, each outstanding Merck restricted stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck restricted stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in two equal installments on May 1, 2022 and May 1, 2023. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 21:26 UTC | Organon & Co. OGN · Entity 4115 | GrantRestricted Stock Units · Derivative | 1,579 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-022198 · doc4.xml · derivative · entry 2 Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,579 Underlying: Common Stock · 1,579 shares Expires 2022-05-03 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock. F3 · kind: In connection with the Separation, each outstanding Merck restricted stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck restricted stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.